Searched for
CAGRISEMA OBESITY DRUG RESULTS
Karnataka: Chief Minister Shivakumar warns gutkha industry of ban if substances are foundKarnataka Chief Minister D K Shivakumar has warned the pan masala and gutkha industry of an outright ban if any intoxicating substances are...- Vice President Radhakrishnan urges collective action to build drug-free IndiaVice President C.P. Radhakrishnan has called for a nationwide, collaborative effort to combat substance abuse, emphasizing the crucial role...
- Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...
- Manipur CM says drug trafficking routes have changed after 2023 crisis, largely diverting through MizoramManipur Chief Minister Yumnam Khemchand Singh revealed that drug trafficking routes have shifted significantly post-2023 crisis, largely di...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Govt to amend NDPS Act to plug loopholes exploited by narco syndicates: Amit ShahUnion Home Minister Amit Shah announced plans to amend the NDPS Act to combat drug syndicates, emphasizing a strict approach against peddle...
- 'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...
- CDSCO asks states, port offices to step up screening to curb imports of illegal drugsIndia's drug regulator is intensifying border screenings to block unapproved medicines from entering the country. Authorities are cracking ...
- Five-min walk break every hour feasible, effective in offsetting harms of prolonged sitting: StudyA recent study reveals that taking a five-minute walking break every hour is the sweet spot for combating the health risks of prolonged sit...
- Staggering amounts of fentanyl hit US streets as the DEA watched and took no action, records showDEA agents in New Mexico allegedly allowed hundreds of thousands of fentanyl pills onto streets between 2023-2025, prioritizing larger case...
- Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
Load More
